Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction

Gut

Volumn 53, Issue 11, 2004, Pages 1549-1552

  De Giorgio, R ^a,b   Sarnelli, G ^c   Corinaldesi, R ^b   Stanghellini, V ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

CHRONIC DISEASE; DISEASE CLASSIFICATION; GASTROINTESTINAL TRANSIT; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; INTESTINE OBSTRUCTION; INTESTINE PSEUDOOBSTRUCTION; MORBIDITY; MYOPATHY; NEUROPATHY; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SYMPTOMATOLOGY;

CHRONIC DISEASE; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; NEUROMUSCULAR DISEASES;

EID: 7244260260     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.043968     Document Type: Review

References (30)

1. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996;334:1106-15.
2. Wood JD. Neural and humoral regulation of gastrointestinal motility. In: Schuster MM, Crowell MD, Koch KL, eds. Gastrointestinal motility in health and disease. London: BC Decker, 2002:19-42.
3. Stanghellini V, Corinaldesi R, Barbara L. Pseudo-obstruction syndromes. Baillieres Clin Gastroenterol 1988;2:225-54.
4. Di Lorenzo C. Pseudo-obstruction: Current approaches. Gastroenterology 1999;116:980-7.
5. Coulie B, Camilleri M. Intestinal pseudo-obstruction. Annu Rev Med 1999;50:37-55.
6. De Giorgio R, Guerrini S, Barbara G, et al. New insights into human enteric neuropathies. Neurogastroenterol Motil 2004;16(suppl 1):143-7.
7. De Giorgio R, Camilleri M. Human enteric neuropathies: Morphology and molecular pathology. Neurogastroenterol Motil 2004 (in press).
8. De Giorgio R, Barbara G, Stanghellini V, et al. The pharmacological treatment of acute colonic pseudo-obstruction. Aliment Pharmacol Ther 2001;15:1717-27.
9. Cogliandro R, Stanghellini V, Cogliandro L, et al. Small bowel motility and natural history of chronic intestinal pseudo-obstruction. Gastroenterology 1998;114:A735.
10. Stanghellini V, Camilleri M, Malagelada J-R. Chronic idiopathic intestinal pseudoobstruction: clinical and intestinal manometric findings. Gut 1987;28:5-12.
11. Krishnamurthy S, Schuffler MD. Pathology of neuromuscular disorders of the small intestine and colon. Gastroenterology 1987;93:610-39.
12. Furness JB, Costo M. The enteric nervous system. Edinburgh: Churchill Livingstone, 1987.
13. Gershon MD, Kirchgessner AL, Wade PR. Functional anatomy of the enteric nervous system. In: Johnson LR, ed. Physiology of the gastrointestinal tract. New York: Raven Press, 1994:381-422.
14. De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004;126:1872-83.
15. Smith W, Gregson N, Foggensteiner L, et al. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement. Gastroenterology 1997;112:1366-71.
16. De Giorgio R, Barbara G, Stonghellini V, et al. Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. Eur J Gastroenterol Hepatol 2000;12:613-16.
17. De Giorgio R, Barbara G, Stanghellini V, et al. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol 2002;97:2454-9.
18. King PH, Redden D, Palmgren JS, et al. Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun 1999;13:435-43.
19. Schäppi MG, Smith W, Milla PJ, et al. Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. Gut 2003;52:752-5.
20. Hall KE, Wiley JW. Neural injury, repair and adaptation in the GI tract. I. New insights into neuronal injury: a cautionary tale. Am J Physiol 1998;274:G978-83.
21. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
22. De Giorgio R, Barbara G, Stanghellini V, et al. Reduced bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). Gastroenterology 2000;118:A4821.
23. Isozaki K, Hirota S, Miyagawa J-I, et al. Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 1997;92:332-4.
24. Boeckxstaens GE, Rumessen JJ, de Wit L, et al. Abnormal distribution of the interstitial cells of Cajal in an adult patient with pseudo-obstruction and megaduodenum. Am J Gastroenterol 2002;97:2120-6.
25. Feldstein AE, Miller SM, El-Youssef M, et al. Chronic intestinal pseudoobstruction associated with altered interstitial cells of Cajal network. J Pediatr Gastroenterol Nutr 2003;36:492-7.
26. Huizinga JD, Thuneberg L, Vanderwinden JM, et al. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders. Trends Pharmacol Sci 1997;18:393-403.
27. Sanders KM, Ördög T, Ward SM. Physiology and pathophysiology of the interstitial cells of Cajal: from bench to bedside. IV. Genetic and animal models of GI motilily disorders caused by loss of interstitial cells of Cajal. Am J Physiol 2002;282:G747-56.
28. Moore SW, Schneider JW, Kaschula ROC. Unusual variations of gastrointestinal smooth muscle abnormalities associated with chronic intestinal pseudoobstruction. Pediatr Surg Int 2002;8:13-20.
29. Smith W, Lake BD, Kamm MA, et al. Intestinal pseudo-obstruction with deficient smooth muscle alpha-actin. Histopathology 1992;21:535-42.
30. Knowles CH, Silk DBA, Darzi A, et al. Deranged smooth muscle α-actin as a biomarker of intestinal pseudo-obstruction: a controlled multinational case series. Gut 2004;53:1583-9.